BioStock: Evaxion Biotech expands its programme with a new indication

Danish Evaxion Biotech, which develops AI-based immunotherapies, has seen encouraging preclinical results with the candidate EVX-03. The company is therefore expanding its programme to include the indication of non-small cell lung cancer. Evaxion plans to submit a regulatory filing in the second half of 2022 for a clinical study within the new indication, which the company believes significantly increases the technology’s possibilities.

Read the article at biostock.se:

https://www.biostock.se/en/2022/07/evaxion-biotech-utokar-sitt-program-med-ny-indikation/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/